Foretinib

Foretinib (formerly known as XL880) is an experimental, orally available multi-targeted tyrosine kinase inhibitor (TKI) under investigation as a potential cancer therapy. It targets key receptor tyrosine kinases (RTKs) involved in tumor growth, angiogenesis, and metastasis. Specifically, foretinib inhibits MET (hepatocyte growth factor receptor), VEGFR2 (vascular endothelial growth factor receptor 2), and RON (Recepteur d'Origine Nantais). By inhibiting these kinases, foretinib aims to disrupt signaling pathways that promote cancer cell proliferation, survival, and spread.

Clinical trials have evaluated foretinib in various solid tumors, including gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, renal cell carcinoma, and papillary renal cell carcinoma. Research focused on determining its efficacy, safety, and pharmacokinetic properties, both as a single agent and in combination with other therapies. While showing some initial promise, further investigation is necessary to establish its role in cancer treatment regimens and to address potential adverse effects. The development and commercialization status of foretinib may change over time as clinical trials progress and regulatory decisions are made.